KalVista Pharmaceuticals (NASDAQ:KALV) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.05), Bloomberg Earnings reports. KalVista Pharmaceuticals had a negative net margin of 1,379.58% and a negative return on equity of 70.26%. The firm had revenue of $1.13 million during the quarter.
KalVista Pharmaceuticals (NASDAQ:KALV) opened at $9.51 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.88 and a quick ratio of 7.88. KalVista Pharmaceuticals has a twelve month low of $5.48 and a twelve month high of $15.80.
In related news, Director Rajeev M. Shah bought 850,000 shares of KalVista Pharmaceuticals stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of $8.50 per share, with a total value of $7,225,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Holdings A/S Novo sold 2,725,283 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $9.64, for a total value of $26,271,728.12. The disclosure for this sale can be found here. 49.10% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “KalVista Pharmaceuticals (KALV) Issues Earnings Results, Misses Expectations By $0.05 EPS” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/16/kalvista-pharmaceuticals-kalv-issues-earnings-results-misses-expectations-by-0-05-eps.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
What are top analysts saying about KalVista Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for KalVista Pharmaceuticals and related companies.